Application receipt dates: August 9, December 9, April 9, 2005 through 2008.
The goal of this program is to fund applications focused on the following areas of research: 1) Phase I or II clinical trials of novel imaging-agents to assure their safety and efficacy, so that further evaluations of the clinical potentials of these agents can proceed; 2) Feasibility studies in image-guided intervention, to establish treatment parameters and early therapeutic efficacy for these methods; and/or 3) Clinical feasibility or "proof-of-principle" studies or clinical trials to demonstrate potential efficacy of promising discoveries in imaging or image-guided therapy methodologies or technologies. Investigators may apply for a maximum of 2 years of funding support using the exploratory or developmental (R21) grant mechanism for up to $250,000 direct costs per year. The anticipated number of awards is three to six per year.

See full description in NIH Guide: PAR-05-114